SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Healthcare >

InVivo Therapeutics Holdings Corp (NVIV)

Add NVIV Price Alert      Hide Sticky   Hide Intro
Moderator: TheHound
Search This Board: 
Last Post: 3/28/2017 8:56:04 AM - Followers: 190 - Board type: Free - Posts Today: 0

About InVivo Therapeutics 

InVivo Therapeutics Corporation is a Cambridge, MA based medical device company founded to develop and commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI).Currently, there are no treatment options for SCI patients to successfully restore function following a spinal cord injury. Existing treatments consist of a collection of approaches that only focus on symptoms of SCI, such as decompression and mechanical stabilization of the spinal cord, rather than on the underlying pathology. InVivo intends to develop its novel Neuro-Spinal Scaffold to treat acute SCI and Neuro-Scaffold Plus Stem Cells to treat chronic SCI. - See more at:

In the Spotlight

October 23, 2015 InVivo Therapeutics Reports Significant Improvement of First Patient Implanted with Neuro-Spinal Scaffold™

October 19, 2015   InVivo Therapeutics Announces Expansion of Number of Patients in Pilot Study

October 1, 2015 Early Promise for a New Paralysis Treatment

September 9, 2015 InVivo Therapeutics Announces Mount Sinai Hospital in New York City as New Site for Neuro-Spinal Scaffold™ Clinical Trial

September 8, 2015 InVivo Therapeutics Announces Enrollment of Fifth Patient in Pilot Spinal Cord Injury Study

August 20, 2015 InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial

August 13, 2015 InVivo Therapeutics’ CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business Network’s “Mornings with Maria”

July 6, 2015 InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold

June 22, 2015 InVivo Therapeutics Receives Notice of Allowance on Patent Covering Broader Compositions for Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells

June 5, 2015- InVivo Therapeutics Announces Enrollment of Third Patient in Pilot Spinal Cord Injury Trial

April 16, 2015InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell

April 8, 2015 - InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

March 26, 2015 - InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial

March 11, 2015 - InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update

February 23, 2015 - InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

February 9, 2015 - InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer

February 5, 2015 - InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board

February 2, 2015 - Video - Second Implantation of InVivo Therapeutics Neuro-Spinal Scaffold In Charlotte

January 22, 2015 - InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial

January 21, 2015 - Zacks Small Cap Research Report- $3.25 Price Target

January 21, 2015 - Jordan's 1st Patient Video

January 21, 2015 - InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold

December 18, 2014 - Microcap - NVIV Research Report **A MUST READ**

December 16, 2014 - InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial

November 11, 2014 - Scottsdale man hopes to walk again after groundbreaking surgery

October 29, 2014 - InVivo Therapeutics Receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial

October 15, 2014 - InVivo Therapeutics Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

April 28, 2014 - InVivo Therapeutics Initiates First Clinical Trial of Neuro-Spinal Scaffold


Ongoing Human Trials:
SEC Filings:
Recent News:
Share Structure:
Investor Presentation:



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVIV News: InVivo Therapeutics Appoints Christopher McNulty as Chief Financial Officer 03/29/2017 08:00:00 AM
NVIV News: InVivo Therapeutics Announces Seventh Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold™ 03/28/2017 08:00:00 AM
NVIV News: InVivo Therapeutics to Present at Needham and Company’s 16th Annual Healthcare Conference 03/27/2017 08:00:00 AM
NVIV News: InVivo to Initiate Cervical Spinal Cord Injury Study 03/23/2017 08:00:00 AM
NVIV News: InVivo Therapeutics Announces Submission to the FDA of Its Nonclinical Studies Module for the Neuro-Spinal Scaffold™ 03/21/2017 08:00:00 AM
News News Alert: InVivo Therapeutics Appoints Christopher McNulty as Chief Financial Officer 03/29/2017 08:00:00 AM
#5791   Great news for the patient!! 7 out of 11 attilathehunt 03/28/17 08:55:22 AM
#5790   here's more pieces. InVivo Therapeutics Announces Seventh Patient Conversion TheHound 03/28/17 08:24:42 AM
#5789   Do you have a link for your assertion? DDobserver 03/24/17 01:59:15 PM
#5788   read bionap, by Jason. another buy reco. ronala 03/24/17 01:15:14 PM
#5787   Looks like a good buying opportunity at these Halks1122 03/23/17 04:15:46 PM
#5786   Besides a broad negative view and concern with DDobserver 03/22/17 08:20:51 AM
#5785   More like a POS issue. scottsmith 03/21/17 05:02:56 PM
#5784   Buying opportunity Devo33 03/21/17 12:59:47 PM
#5783   it's a sector and broad market issue. TheHound 03/21/17 12:50:54 PM
#5782   Was today's news bad? What am I Johnny Penstock 03/21/17 12:25:38 PM
#5781   also, Thomson Reuters has a buy on nviv ronala 03/21/17 10:32:24 AM
#5780   $NVIV news ----> TheHound 03/20/17 10:18:25 AM
#5779   Ronala, I looked into these links you provided and DDobserver 03/18/17 05:10:23 AM
#5777   need a link? TheHound 03/17/17 11:01:47 PM
#5776   Thank you for the response. I shall look DDobserver 03/17/17 10:08:15 PM
#5775   still waiting.... TheHound 03/17/17 05:30:44 PM
#5774   just google nviv stock recommendations, there are ronala 03/17/17 04:43:30 PM
#5768   haven't you had a chance to respond to TheHound 03/17/17 01:10:30 PM
#5767   Your source?????? DDobserver 03/17/17 10:13:06 AM
#5766   did I see a new Strong Buy for ronala 03/17/17 10:11:58 AM
#5757   agree. im in. TheHound 03/16/17 03:07:27 PM
#5756   horseshit. there's been no major sell off by TheHound 03/16/17 02:02:53 PM
#5755   LEAD by EXAMPLE DDobserver 03/16/17 01:04:56 PM
#5743   what link? what major insider sell off? show TheHound 03/15/17 10:05:38 AM
#5742   everyone, calm. Remember there is a new ronala 03/15/17 10:04:51 AM
#5741   Why yes I have heard and have read DDobserver 03/15/17 09:50:02 AM
#5740   I think this is a good entry point akocaman 03/15/17 04:44:18 AM
#5739   LOD close. I see this one going lower Halks1122 03/14/17 05:04:56 PM
#5734   nope. i dont see what ur talking about. TheHound 03/14/17 08:43:51 AM
#5733   LEAD by EXAMPLE DDobserver 03/14/17 08:39:45 AM
#5732   i looked at the filings and dont see TheHound 03/13/17 09:07:13 PM
#5731   This kind of information has been weighing on rosemountbomber 03/13/17 08:36:20 PM
#5730   This kind of information has been weighing on rosemountbomber 03/13/17 08:36:18 PM
#5729   From Form K10 3-7-2017 DDobserver 03/11/17 10:10:27 AM
#5728   Devos was a speculation from my post. I DDobserver 03/10/17 02:25:35 PM
#5727   Uh, no. BioBull1 03/10/17 01:48:34 PM
#5726   What I asked was the source of your DDobserver 03/10/17 11:39:00 AM
#5725   'Tweaking' as it was put can not occur BioBull1 03/10/17 10:44:07 AM
#5724   And the source for your assurance come from? DDobserver 03/10/17 10:15:18 AM
#5723   I can assure you that is not the case BioBull1 03/09/17 05:30:55 PM
#5722   It could with 30 sites but even if DDobserver 03/09/17 01:23:51 PM
#5721   IMHO the lack of enrollments is due to Devo33 03/09/17 12:17:48 PM
#5720   That is great to hear. akocaman 03/09/17 10:04:10 AM
#5719   I agree with you that the current pace BioBull1 03/09/17 09:12:04 AM
#5718   Sixty percentage of enrollment over a two year DDobserver 03/09/17 08:41:31 AM
#5717   InVivo Therapeutics Announces Enrollment of New Patient into MDizzle 03/09/17 08:13:00 AM
#5716   I agree missed opportunities. However, with this technology DDobserver 03/08/17 11:29:43 AM
#5715   This has been a missed opportunity on many levels. BioBull1 03/08/17 11:16:04 AM
#5714   I was always told to follow the insiders. DDobserver 03/08/17 10:45:22 AM
#5713   No insider buying, no real analyst coverage, MINIMAL BioBull1 03/08/17 09:20:51 AM